MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
1.155
-0.035
-2.94%
Opening 10:08 12/09 EST
OPEN
1.160
PREV CLOSE
1.190
HIGH
1.179
LOW
1.150
VOLUME
38.70K
TURNOVER
27.53K
52 WEEK HIGH
14.50
52 WEEK LOW
1.130
MARKET CAP
45.35M
P/E (TTM)
-0.4030
1D
5D
1M
3M
1Y
5Y
BARK And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
Benzinga · 11/28 13:29
Immunic President, CEO Buys 8K Shares At Average Price Of $1.35/Share
Benzinga · 11/23 15:16
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 11/17 13:07
Immunic Touts Positive Vidofludimus Calcium Data In Multiple Sclerosis Candidate
Benzinga · 11/17 13:04
BRIEF-Immunic Reports New Data Mid-Stage Trial For Multiple Sclerosis Drug
Reuters · 11/17 12:17
Immunic Reports New Data From Phase 2 EMPhASIS Trial Of Vidofludimus Calcium In Relapsing-Remitting Multiple Sclerosis Supporting The Drug's Neuroprotective Potential
Benzinga · 11/17 11:31
Recap: Immunic Q3 Earnings
Benzinga · 11/03 10:59
BRIEF-Immunic, Inc. Reports Third Quarter 2022 Financial Results
Reuters · 11/03 10:43
More
About IMUX
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is focused on three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (RORyt), an immune cell-specific isoform of RORy; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis (MS), psoriasis and gastrointestinal diseases.

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.